Natural Capsules quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	48.7	45.2	+7.8%
EBITDA	1.1	0.3	+250.8%
EBITDA margin	2.3%	0.7%	+1.6 pts
Profit before tax	−5.8	−6.1	—
Net profit	−5.7	−5.6	—
EPS	−₹5.55	−₹5.40	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025

Expenses
	48.7	58.5	37.7	45.8	45.2	45.0
	2.4	0.8	0.4	0.2	0.4	0.3
	51.1	59.2	38.2	46.0	45.6	45.3
	28.9	29.5	25.3	24.8	23.6	22.9
	−3.0	6.0	−6.4	−0.5	−0.0	−0.1
	5.2	5.5	5.7	5.5	5.4	3.7
	5.0	2.9	2.8	2.7	2.5	1.6
	4.3	4.3	4.4	4.3	4.2	2.2
	16.4	16.2	15.4	16.8	15.9	14.1
	56.9	64.3	47.3	53.7	51.6	44.4
	1.1	1.3	−2.3	−0.9	0.3	4.4
	−3.2	−3.0	−6.7	−5.2	−3.9	2.2
Profit
	−5.8	−5.1	−9.1	−7.7	−6.1	0.9
	−5.8	−5.1	−9.1	−7.7	−6.1	0.9
	1.5	1.9	0.0	0.9	0.9	−0.3
	−1.6	−2.0	−2.0	−1.6	−1.4	0.6
	−0.1	−0.1	−2.0	−0.7	−0.5	0.4
	−5.7	−5.0	−7.1	−7.0	−5.6	0.5
	−5.7	−5.0	−7.1	−7.0	−5.6	0.5
	0.0	−0.0	0.0	0.0	0.0	−0.4
	−5.7	−5.0	−7.1	−7.0	−5.6	0.1
	−4.0	−3.4	−7.1	—	—	—
	−1.8	−1.5	0.0	—	—	—
Per share
	−₹5.55	−₹4.82	−₹6.88	−₹6.76	−₹5.40	₹0.13
	−₹5.54	−₹4.80	−₹6.85	−₹6.76	−₹5.40	₹0.13
Other comprehensive income — detail
	0.0	−0.0	—	—	—	−0.4
	—	−0.0	—	—	—	—
	0.0	0.0	—	—	—	0.4
	−4.0	−3.4	−7.1	—	—	—
	−1.8	−1.5	0.0	—	—	—
Per share — as-filed variants
	−₹5.55	−₹4.82	−₹6.88	−₹6.76	−₹5.40	₹0.13
	−₹5.54	−₹4.80	−₹6.85	−₹6.76	−₹5.40	₹0.13
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	22.8	23.0	18.8	21.5	21.6	22.2
	46.7%	39.3%	49.7%	46.9%	47.8%	49.3%
Adjusted (ex-exceptional items) — derived
	−5.8	−5.1	−9.1	−7.7	−6.1	0.9
	−5.7	−5.0	−7.1	−7.0	−5.6	0.5
	−₹5.55	−₹4.82	−₹6.88	−₹6.76	−₹5.40	₹0.13

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCAPSUQ₹136.44

Natural Capsules Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersNECLIFE AAREYDRUGS BALPHARMA ALPA KREBSBIO MEDICAMEQ MEDICO VINEETLABMcap ₹142 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	45.0	45.2	45.8	37.7	58.5	48.7
Other Income	0.3	0.4	0.2	0.4	0.8	2.4
Total Income	45.3	45.6	46.0	38.2	59.2	51.1
Expenses
+ Cost of Materials Consumed	22.9	23.6	24.8	25.3	29.5	28.9
+ Changes in Inventories	-0.1	-0.0	-0.5	-6.4	6.0	-3.0
+ Employee Benefit Expense	3.7	5.4	5.5	5.7	5.5	5.2
+ Finance Costs	1.6	2.5	2.7	2.8	2.9	5.0
+ Depreciation & Amortisation	2.2	4.2	4.3	4.4	4.3	4.3
+ Other Expenses	14.1	15.9	16.8	15.4	16.2	16.4
Total Expenses	44.4	51.6	53.7	47.3	64.3	56.9
EBITDA	4.4	0.3	-0.9	-2.3	1.3	1.1
EBIT	2.2	-3.9	-5.2	-6.7	-3.0	-3.2
Profit
PBT before Exceptional Items	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
Pretax Income	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
+ Current Tax	-0.3	0.9	0.9	0.0	1.9	1.5
+ Deferred Tax	0.6	-1.4	-1.6	-2.0	-2.0	-1.6
Tax Expense	0.4	-0.5	-0.7	-2.0	-0.1	-0.1
Net Income	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
+ Net Income — Continuing Ops	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
+ Other Comprehensive Income	-0.4	0.0	0.0	0.0	-0.0	0.0
Total Comprehensive Income	0.1	-5.6	-7.0	-7.1	-5.0	-5.7
Net Income to Common	—	—	—	-7.1	-3.4	-4.0
Minority Interest	—	—	—	0.0	-1.5	-1.8
Per Share
Basic EPS	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Diluted EPS	0.13	-5.40	-6.76	-6.85	-4.80	-5.54
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.4	—	—	—	-0.0	0.0
+ Items NOT to be Reclassified to P&L	—	—	—	—	-0.0	—
+ Tax on Items NOT to be Reclassified	0.4	—	—	—	0.0	0.0
Comprehensive Income — Owners of Parent	—	—	—	-7.1	-3.4	-4.0
Comprehensive Income — Non-controlling Interests	—	—	—	0.0	-1.5	-1.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Diluted EPS — Continuing Operations	0.13	-5.40	-6.76	-6.85	-4.80	-5.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	22.2	21.6	21.5	18.8	23.0	22.8
Gross Margin %	49.29	47.85	46.91	49.74	39.30	46.72
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
Net Income Adj (tax-effected)	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
EPS Adj	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	40.00	0.48	—	—	—	—
Paid Up Equity Capital	10.3	10.3	10.3	10.3	10.4	10.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Natural Capsules quarterly results

Natural Capsules (NSE: NATCAPSUQ) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net loss attributable to shareholders was ₹4 crore, narrower than the loss of ₹5.6 crore in Q1 FY26 and wider than the loss of ₹3.4 crore in Q4 FY26. Revenue from operations was ₹48.7 crore, up 7.8% year on year and down 16.7% from the previous quarter.

Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 12 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net loss: −₹4 Crloss ₹5.6 Cr in Q1 FY26loss ₹3.4 Cr in Q4 FY26
Q1 FY27 revenue: ₹48.7 Cr+7.8% vs Q1 FY26−16.7% vs Q4 FY26
Q1 FY27 operating margin: −6.6%+2.0 pts vs Q1 FY26−1.5 pts vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹7 CrRevenue ₹45.8 Cr
Q1 FY27 EPS (basic): −₹5.55

Questions

When will Natural Capsules announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 13 November 2025.

What will Natural Capsules' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss attributable to shareholders was ₹7 crore and revenue from operations ₹45.8 crore. The latest quarter, Q1 FY27, had a net loss of ₹4 crore and revenue of ₹48.7 crore.

What were Natural Capsules' Q1 FY27 results?

Consolidated net loss attributable to shareholders was ₹4 crore, narrower than the loss of ₹5.6 crore in Q1 FY26 and wider than the loss of ₹3.4 crore in Q4 FY26. Revenue from operations was ₹48.7 crore, up 7.8% year on year and down 16.7% from the previous quarter.

How has Natural Capsules' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a loss of ₹7 crore in Q2 FY26, a loss of ₹7.1 crore in Q3 FY26, a loss of ₹3.4 crore in Q4 FY26 and a loss of ₹4 crore in Q1 FY27. That is a combined loss of ₹21.5 crore over the four quarters. Revenue from operations: ₹45.8 crore, ₹37.7 crore, ₹58.5 crore and ₹48.7 crore.

What was Natural Capsules' net profit in FY26?

Consolidated net profit attributable to shareholders was a loss of ₹17.1 crore in FY26 (April 2025–March 2026), against a profit of ₹62 lakh in FY25.

What was Natural Capsules' revenue in FY26?

Revenue from operations was ₹187 crore in FY26 (April 2025–March 2026), up 10.6% from ₹169 crore in FY25.

Where do these Natural Capsules figures come from?

From Natural Capsules' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.